Table III.
CST changes in the different groups.
| A, <69 | |||
|---|---|---|---|
| Visual acuity letter score | Aflibercept (n=40) | Ranibizumab (n=40) | P-value |
| Eyes (n) | 18 | 21 | |
| Mean change in CST from baseline (µm) | −171±48.5 | −154±43.6 | 0.127 |
| CST <250 µm at 1 year | 11 (61.1) | 8 (38.1) | 0.152 |
| B, ≥69 | |||
| Visual acuity letter score | Aflibercept (n=40) | Ranibizumab (n=40) | P-value |
| Eyes (n) | 22 | 19 | |
| Mean change in CST from baseline (µm) | −113±32.7 | −112±30.8 | 0.923 |
| CST <250 µm at 1 year | 12 (54.5%) | 8 (38.1) | 0.427 |
Values are expressed as n (%) or the mean ± standard deviation. CST, central subfield thickness.